Open Access

Interleukin 25 (IL‑25) expression in cholangiocarcinoma

  • Authors:
    • Supakit Kaewsarabhumi
    • Tanakorn Proungvitaya
    • Temduang Limpaiboon
    • Patcharaporn Tippayawat
    • Doungdean Tummanatsakun
    • Attapol Titapun
    • Prakasit Sa‑Ngaimwibool
    • Siriporn Proungvitaya
  • View Affiliations

  • Published online on: October 15, 2020     https://doi.org/10.3892/mco.2020.2154
  • Article Number: 84
  • Copyright: © Kaewsarabhumi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Various cytokines are involved in carcinogenesis and tumor progression. Some tumor cells produce cytokines by themselves. Using secretome analysis, a high expression of APEX‑1 was found in cholangiocarcinoma (CCA) cell lines. During this secretome analysis, it was found that CCA cell lines overexpressed some cytokines and related molecules, including interleukin 25 (IL‑25). In the present study, we first performed precise secretome analysis on cytokines and related molecules in CCA cell lines and identified that IL‑25 was overexpressed in CCA cell lines. Then, using immunohistochemical methods, we investigated the expression of IL‑25 in the cancer tissues from 20 CCA patients in Northeast Thailand. Correlation between IL‑25 expression levels and patients' clinical parameters were analyzed. The results showed that IL‑25 expression was significantly (P<0.0001) higher in cancerous tissues than in the normal bile ducts and in the adjacent tissues. Overexpression of IL‑25 protein in CCA tissue was confirmed using western blot analysis. Moreover, IL‑25 expression in cancerous tissues was significantly (P<0.0015) higher in CCA patients with metastasis than in CCA patients without metastasis. Survival analysis revealed that a high expression of IL‑25 was correlated with shorter survival time of CCA patients (P=0.0260). Aberrant expression of IL‑25 in CCA tissue was associated with tumor metastasis and poor prognosis, suggesting that IL‑25 is a potential prognostic biomarker. Biological roles of IL‑25 in CCA genesis and progression should be explored in future.
View Figures
View References

Related Articles

Journal Cover

December-2020
Volume 13 Issue 6

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kaewsarabhumi S, Proungvitaya T, Limpaiboon T, Tippayawat P, Tummanatsakun D, Titapun A, Sa‑Ngaimwibool P and Proungvitaya S: Interleukin 25 (IL‑25) expression in cholangiocarcinoma. Mol Clin Oncol 13: 84, 2020
APA
Kaewsarabhumi, S., Proungvitaya, T., Limpaiboon, T., Tippayawat, P., Tummanatsakun, D., Titapun, A. ... Proungvitaya, S. (2020). Interleukin 25 (IL‑25) expression in cholangiocarcinoma. Molecular and Clinical Oncology, 13, 84. https://doi.org/10.3892/mco.2020.2154
MLA
Kaewsarabhumi, S., Proungvitaya, T., Limpaiboon, T., Tippayawat, P., Tummanatsakun, D., Titapun, A., Sa‑Ngaimwibool, P., Proungvitaya, S."Interleukin 25 (IL‑25) expression in cholangiocarcinoma". Molecular and Clinical Oncology 13.6 (2020): 84.
Chicago
Kaewsarabhumi, S., Proungvitaya, T., Limpaiboon, T., Tippayawat, P., Tummanatsakun, D., Titapun, A., Sa‑Ngaimwibool, P., Proungvitaya, S."Interleukin 25 (IL‑25) expression in cholangiocarcinoma". Molecular and Clinical Oncology 13, no. 6 (2020): 84. https://doi.org/10.3892/mco.2020.2154